This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Anger Gets You Nowhere


When asked about current market conditions, Ouimet said there are extreme weather events every year and they don't have a sizable impact on the company's profitability. A decline in gasoline prices, however, does make a difference as Mom and Dad are likely to spend a little more at the park if the drive to and from costs a little less.

Ouimet said Cedar Fair is always looking for acquisitions, but noted that great opportunities are harder to find. There have been no new parks built in the past three decades mainly because of the costs involved and the fact that the market has been absorbed by existing parks.

Finally, when asked about the current season, Ouimet mentioned that season ticket sales are up over last year and many of the company's parks are at record levels of ticket sales. He said driving to a local amusement park is far simpler than traveling by air, and that trend won't be changing anytime soon.

Cramer continued his recommendation of Cedar Fair saying the company has a lot more upside to come.

Beyond the Business Section

Sometimes the best investment ideas don't come from the business section, Cramer told viewers. Take Alkermes (ALKS), a drug company whose drug Vivitrol is changing the way prescription drug abuse is treated in our country.

Citing a recent article in the New York Times, prescription drug abuse is a problem that needs to "urgently be solved," as some 54% of all overdose deaths are now attributed to painkillers and not traditional illegal narcotics. Enter Vivitrol, a drug that blocks the receptors in the brain that respond to opiates, rendering patients unable to get high. Better still, Vivitrol is only needed once a month.

Cramer said this drug is a huge leap forward from traditional treatments that merely replace dangerous opiates with less dangerous ones and require daily doses. Of the estimated 1.6 million people addicted to opiates, nearly 75% of them will seek treatment eventually, making the market opportunity for Alkermes a sizable one.

While critics cite the high cost of the drug as a major drawback, recent state government reports has found that when considering the total cost of treating an addicted patient, the cost of Vivitrol actually saves money.

2 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs